Posted by SLS on July 4, 2000, at 9:28:43
In reply to Re: Adrafinil? Sulpiride? » SLS, posted by KarenB on July 4, 2000, at 0:19:37
Dear Karen,
Thank you SO, SO much!
Your comments regarding low-dose sulpiride and mood stabilization are fascinating and extremely important.
In what ways has sulpiride acted as a mood stabilizer? How was your mood unstable previously?
"Anergic" means without energy. Bipolar depression is usually very anergic (low-energy), and in many ways appears similar to atypical unipolar depression.
What is it about your case that has led to a diagnosis of bipolar disorder?
ADD / ADHD and bipolar disorder often occur simultaneously. I believe that Provigil is currently being studied for use in ADD. Initial results are encouraging. However, I could not find anything on Medline regarding this. I imagine adrafinil would have the same utility. I can find nothing in the Provigil (modafinil) package insert that would suggest that it cannot be combined with Dexedrine, Adderal, or Ritalin. The only interaction listed is that Ritalin may delay the absorption of Provigil by one hour if they are taken simultaneously. I do not know to what extent this information is applicable to adrafinil. I'm sure your doctor will be able to tell you with certainty. I included relevant information below. Perhaps adrafinil will improve your mood without improving ADD. In this case, adding a stimulant may be desirable.
Did sulpiride produce any improvement in PMS?
I can't tell you how much it means to me that you posted such a detailed reply. Thanks again.
Sincerely and Appreciatively,
Scott
P.S. I haven't menstruated since beginning sulpiride either. I don't know how to feel about that.
------------------------------------------------------------8: J Clin Pharmacol 1998 Oct;38(10):971-8
Comparison of the single-dose pharmacokinetics and tolerability of modafinil and
dextroamphetamine administered alone or in combination in healthy male
volunteers.Wong YN, Wang L, Hartman L, Simcoe D, Chen Y, Laughton W, Eldon R, Markland C,
Grebow PCephalon, Inc., West Chester, Pennsylvania, USA.
An open-label, randomized, crossover study was performed in healthy male
volunteers to evaluate the potential pharmacokinetic and pharmacodynamic
interactions and tolerability of single oral doses of modafinil (200 mg) and
dextroamphetamine (10 mg). Blood samples were collected for determination of
plasma levels of modafinil, the acid and sulfone metabolites of modafinil, and
dextroamphetamine at intervals through 48 hours after administration for each
treatment. Vital signs (blood pressure and pulse rate) were measured through 48
hours, and electrocardiograms were measured through 24 hours after
administration. Pharmacokinetic parameters were determined using
noncompartmental methods. The data collected in this study of 24 healthy
volunteers suggest that concomitant administration of single oral doses of
modafinil and dextroamphetamine has no clinically significant effects on the
pharmacokinetic profile of either agent. Although there was a slightly greater
incidence of adverse events when modafinil and dextroamphetamine were
administered together, the concomitant administration of the two drugs was well
tolerated.Publication Types:
Clinical trial
Clinical trial, phase i
Randomized controlled trialPMID: 9807980, UI: 99023133
----------------------------------------------------------
SOURCE: Cephalon, Inc.Physician Reports First U.S. Study of Modafinil (PROVIGIL(R)) in ADHD
WEST CHESTER, Pa., May 18 /PRNewswire/ -- A study presented today at the annual meeting of the American Psychiatric Association (APA) in Chicago described the effects of modafinil and the drug's potential as a treatment for Attention Deficit Hyperactivity Disorder (ADHD). The study conducted by Fletcher B. Taylor, M.D., of Tacoma, WA, compared modafinil to dextroamphetamine, a commonly used amphetamine, and placebo in adults with ADHD. Results of the study demonstrated that an average daily dose of approximately 200 mg of modafinil produced a statistically and clinically significant reduction (30 percent or more) in the symptoms of ADHD as measured by the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) ADHD Behavior Checklist for Adults, compared to placebo. Modafinil is marketed as PROVIGIL® (modafinil) Tablets [C-IV] in several countries, including the United States, by Cephalon, Inc. (Nasdaq: CEPH - news) for the treatment of excessive daytime sleepiness associated with narcolepsy.
poster:SLS
thread:39176
URL: http://www.dr-bob.org/babble/20000630/msgs/39325.html